Iron Deficiency Injectable Market Size Reaches $16.74 Billion In 2026: What Is Driving Growth?

Iron Deficiency Injectable Market Report

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Iron Deficiency Injectable Market Size And Revenue Outlook Through 2030

The market for injectable treatments for iron deficiency has shown robust growth over recent years. Projections indicate expansion from $15.22 billion in 2025 to $16.74 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.0%. Historically, this growth has been driven by factors such as the widespread occurrence of iron deficiency anemia, the restricted effectiveness of oral iron treatments, a rise in chronic kidney disease diagnoses, an increase in hospital-administered infusion therapies, and the broader clinical adoption of injectable iron solutions.

The iron deficiency injectable market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $25.69 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.3%. This projected increase is primarily driven by factors such as a growing elderly population, the rising incidence of cancer and IBD, the broadening of homecare infusion services, enhanced safety characteristics of contemporary formulations, and expanding access to healthcare in developing regions. Key developments expected during this period involve an increasing preference for injectable iron over oral alternatives, its more widespread application in chronic kidney disease management, the proliferation of day-care and brief infusion protocols, an increase in generic injectable iron products, and greater adoption in oncology and chronic disease treatment.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=81480112&type=smp&name=Iron%20Deficiency%20Injectable%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Iron Deficiency Injectable Market Growth Factors: What’s Supporting Expansion?

The rising occurrence of polycystic ovary syndrome (PCOS) is anticipated to drive the expansion of the iron deficiency injectables market in the future. PCOS, a widespread hormonal condition, impacts individuals with ovaries, predominantly women of reproductive age. This syndrome results in iron overload, which contributes to substantial blood loss during menstruation and renders patients anemic; these conditions can be addressed by injectable iron deficiency medications. As an illustration, in June 2023, data from the World Health Organization, a US-based specialized health agency, indicated that an estimated 8–13% of women of reproductive age worldwide are affected by polycystic ovary syndrome (PCOS), with 70% of these cases going undiagnosed. Consequently, the widespread occurrence of polycystic ovary syndrome (PCOS) is fueling the expansion of the iron deficiency injectables market.

Iron Deficiency Injectable Market Segment Performance And Emerging Opportunities

The iron deficiency injectable market covered in this report is segmented –

1) By Type: Iron Dextran, Ferric Carboxymaltose

2) By Branded or Generics: Branded, Generics

3) By Application: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Applications

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Ferric Carboxymaltose: Injectafer, Ferinject

Iron Deficiency Injectable Market Industry Trends: What’s Reshaping Demand?

Leading companies in the iron deficiency injectables market are developing new therapies, such as INJECTAFER, to maintain their competitive position. For example, in June 2023, Daiichi Sankyo Company, a US-based healthcare company, along with American Regent Inc., a US-based injectables manufacturer, launched INJECTAFER (ferric carboxymaltose injection) for iron deficiency, following its approval by the Food And Drug Administration, a US-based government agency. This product stands as the first and only intravenous iron replacement therapy approved by the FDA for adult patients experiencing chronic and progressive heart failure. INJECTAFER was evaluated in more than 40 clinical trials, involving over 8,800 participants from various countries. This latest approval further supports INJECTAFER’s demonstrated and successful use in these patients, including adult and pediatric patients with iron-deficient anemia and heart failure.

Iron Deficiency Injectable Market Key Players: Which Companies Lead Industry Competition?

Major companies operating in the iron deficiency injectable market are Daiichi Sankyo Company Limited, Pfizer Inc., Fresenius Medical Care, AbbVie Inc., Bayer AG, AstraZeneca Plc, GSK Plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., B Braun Medical Inc., Sandoz, Fresenius Kabi AG, AMAG Pharmaceuticals Inc., Luitpold Pharmaceuticals Inc., Akebia Therapeutics Inc., Covis Pharma GmbH , Keryx Biopharmaceuticals Inc., Rockwell Medical Inc., American Regent Inc.

View The Full Iron Deficiency Injectable Market Report:

https://thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Iron Deficiency Injectable Market Global Footprint: Which Region Leads The Market?

North America was the largest region in the iron deficiency injectable market in 2025. The regions covered in the iron deficiency injectable market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model